GVRP and Yurogen Biosystems Announce Partnership to Enhance Biologics Drug Discovery in India

BusinessWire India
Hyderabad (Telangana) [India], February 20: GV Research Platform (GVRP) today announced a strategic distribution partnership with Yurogen Biosystems, a global life sciences company specialising in custom biologics development. The collaboration is aimed at expanding access for Indian biotechnology and pharmaceutical companies, as well as academic research institutions, to advanced antibody discovery capabilities supporting early-stage drug discovery and translational research.
Under this partnership, GVRP will serve as the commercial interface for Yurogen Biosystems in India, enabling streamlined market access, client engagement, and program coordination, while all scientific execution and service delivery will continue to be carried out by Yurogen Biosystems.
The collaboration responds to the growing demand within India's life sciences ecosystem for globally benchmarked antibody discovery services, particularly in areas requiring deep biological insight at early stages of research. By combining Yurogen's scientific expertise with GVRP's understanding of the Indian research ecosystem, the partnership enables smoother and more efficient engagement for domestic innovators.
Partnership Highlights
Advanced antibody discovery platform: Access to Yurogen Biosystems' proprietary SMab™ single B-cell technology, enabling rapid generation of high-affinity monoclonal antibodies to support early discovery and translational research programs.
End-to-end antibody development capabilities: Customised antibody engineering and production supported by comprehensive antibody-based solutions for research, diagnostics, and antibody-related drug development applications.
Broad monoclonal antibody capabilities: Development of rabbit, camelid (llama), and fully human monoclonal antibodies tailored for diverse biological targets and therapeutic strategies.
Accelerated discovery timelines: Optimised workflows designed to reduce development timelines while maintaining high performance, reproducibility, and scientific rigor required for early-stage biologics research.
Flexible and clearly structured programs: Engagement models designed to ensure clarity on ownership and freedom to operate, with antibody clones and related research outputs delivered without IP encumbrances from the platform.
Commenting on the partnership, Kalyan Korisapati, Co-Founder & CEO of GV Research Platform, said: "This partnership with Yurogen Biosystems reflects our focus on expanding meaningful access to advanced monoclonal antibody discovery platforms such as SMab™. By enabling faster and more precise early discovery, we aim to support Indian innovators in advancing targeted therapies efficiently. As the local commercial interface, GVRP will simplify engagement and facilitate access to globally benchmarked discovery capabilities."
Dr. Yang Lou, CEO of Yurogen Biosystems, added: "India is emerging as an important centre for early-stage biomedical research. Partnering with GVRP allows us to engage more closely with the Indian biopharma community through a trusted local presence, while continuing to deliver our services with the same scientific rigour and quality standards."
Through this partnership, GVRP and Yurogen Biosystems aim to strengthen global scientific collaboration and support the continued growth of India's drug discovery ecosystem by improving access to specialised early discovery capabilities.
(ADVERTORIAL DISCLAIMER: The above press release has been provided by BusinessWire India. ANI will not be responsible in any way for the content of the same)